poisar

Stocks · News reference

Guggenheim Initiates Kazia Therapeutics at Buy With $35 Price Target

Fiscal.ai

Guggenheim has initiated coverage on Kazia Therapeutics with a 'Buy' rating and a price target of $35.00 per share.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading